IM CAB LA

Phase 2Small molecule

GSK

IM CAB LA is one of 10 small molecule programs targeting HIV-1. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1Not yet recruiting

HIV-1Phase 2

Not yet recruiting

Competition

Competitive Landscape

11 competitors in HIV-1

#DrugCompanyPhaseTrials

Cabenuva

GSK

Approved

4 2

Biktarvy

Gilead

Phase 3

3 3

Sunlenca

Gilead

Phase 3

1 4

B/F/TAF

Gilead

Phase 3

2 5

ISL/LEN

Gilead

Phase 3

1 6

VRC07-523LS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

2 7

PGT121.414.LS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 8

IM CAB LA

GSK

Phase 2

1 9

Thymopentin

IImmunobiology Research Institute

Preclinical

2 10

Sirtuin Histone Deacetylase Inhibitor

FFederal University of São Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Not yet recruiting

HIV-1

NCT07275606

Clinical

Trials by Indication[1]

Pregnant Women1 trial

Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women

Terminated· GSK logo

GSK·Phase 1·NCT02999100·31 enrolled

Oxytocin1 trial

Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers

Completed· GSK logo

GSK·Phase 1·NCT02542813·16 enrolled

HIV-11 trial

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

Not yet recruiting· GSK logo

GSK·Phase 1/2·NCT07275606·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IM CAB LA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IM CAB LA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IM CAB LA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

IM CAB LA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Pregnant Women1 trial

Oxytocin1 trial

HIV-11 trial

References

Drug Info

Quick Facts

Related News